Repligen (NASDAQ:RGEN) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Repligen (NASDAQ:RGEN – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other equities analysts have also issued reports on RGEN. UBS Group boosted their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Barclays boosted their target price on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Weiss Ratings lowered shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, January 30th. Finally, Wells Fargo & Company increased their price objective on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $179.62.

View Our Latest Research Report on RGEN

Repligen Price Performance

Shares of RGEN opened at $142.18 on Friday. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.00 billion, a PE ratio of 7,112.56, a PEG ratio of 2.59 and a beta of 1.13. Repligen has a 12-month low of $102.96 and a 12-month high of $175.77. The business has a 50-day simple moving average of $161.90 and a two-hundred day simple moving average of $145.25.

Insider Buying and Selling at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares in the company, valued at $14,783,181. The trade was a 0.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 49,657 shares of company stock worth $7,721,077. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently bought and sold shares of the company. Americana Partners LLC bought a new position in Repligen in the 4th quarter worth approximately $224,000. Global Retirement Partners LLC lifted its position in shares of Repligen by 404.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,755 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 1,407 shares in the last quarter. Intrust Bank NA bought a new position in shares of Repligen in the fourth quarter worth $267,000. Jag Capital Management LLC bought a new position in shares of Repligen in the fourth quarter worth $221,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Repligen by 32.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,464 shares of the biotechnology company’s stock valued at $731,000 after purchasing an additional 1,093 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

(Get Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Read More